Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

235

Enrollment

NETWORK

Sponsor class

Conditions

Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Positive Breast Carcinoma
Invasive Breast Carcinoma

Interventions

DRUG: Chemotherapy
PROCEDURE: Computed Tomography
OTHER: Fludeoxyglucose F-18
PROCEDURE: Positron Emission Tomography
PROCEDURE: Surgical Procedure

Sponsor

ECOG-ACRIN Cancer Research Group